Trodelvy(Sacituzumab Govitecan-Hziy)
GILD
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Gilead Sciences, Inc.
$6.2M
Medicare cost, 2024
$6.2M
Medicare cost, 2024
Medicare drug plans spent $6.2 million on Trodelvy (sacituzumab govitecan-hziy) in 2024, for 319 prescriptions and refills filled by 67 patients. Spending rose 36% from 2023 to 2024. At about $19,509 per prescription it is a high-cost drug. New York accounts for the most spending ($1.5 million, 24% of the total).
Medicare cost, 2024
$6.2M
+36.3% from 2023
Prescriptions
319
$19,509.31 per claim
Patients
67
68 prescribers
Total spending, 2024
$6.2M
$92,887.61 per patient
Questions and answers
How much does Medicare spend on Trodelvy?
Medicare prescription drug plans paid $6.2M for Trodelvy in 2024, for 319 prescriptions and refills to 67 patients (up 36.3% from 2023). The average cost per claim was $19,509.31.
Which state spends the most on Trodelvy?
New York had the highest Medicare cost for Trodelvy in 2024: $1.5M for 73 claims, followed by California ($872K).
Who prescribes Trodelvy the most?
Samer S Kasbari, hematology-oncology in Goldsboro, NC, had the highest Medicare cost for Trodelvy in 2024: 12 claims costing $354K.
Who makes Trodelvy?
Trodelvy is made by Gilead Sciences, Inc. (GILD), listed in the Medicare spending data as Gilead Sciences.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Trodelvy was $6.2M in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Trodelvy, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Samer S Kasbari Goldsboro, NC | Hematology-Oncology | 12 | Under 11 | $354K |
| Syed S Rafique Greenwood, MS | Hematology-Oncology | 15 | Under 11 | $329K |
| 1407859259 | Hematology-Oncology | 11 | Under 11 | $296K |
| Rohit Kapoor Live Oak, TX | Hematology-Oncology | 14 | Under 11 | $274K |
| Satish A Shah Gettysburg, PA | Hematology-Oncology | 18 | Under 11 | $218K |
| Anna A Niewiarowska Bethlehem, PA | Hematology-Oncology | 14 | Under 11 | $205K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 35 | 153 | 35 | $3.0M |
| 2023 | 55 | 231 | 63 | $4.6M |
| 2024 | 68 | 319 | 67 | $6.2M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Gilead Sciences | 319 | $6.2M |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.